Phase IIa study of the immunogenicity and safety of the novel Staphylococcus aureus vaccine V710 in adults with end-stage renal disease receiving hemodialysis

Clinical and Vaccine Immunology

Volumn 19, Issue 9, 2012, Pages 1509-1516

  Moustafa, Moustafa ^a   Aronoff, George R ^b   Chandran, Chandra ^c   Hartzel, Jonathan S ^d   Smugar, Steven S ^d   Galphin, Claude M ^e   Mailloux, Lionel U ^f   Brown, Elizabeth ^d   DiNubile, Mark J ^d   Kartsonis, Nicholas A ^d   Guris, Dalya ^d  

^a South Carolina Nephrology and Hypertension Center   (United States)

^b University of Louisville School of Medicine   (United States)

^c ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Southeastern Renal Research Institute   (United States)

^f DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXYPHOSPHATE SULFATE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; IRON SURFACE DETERMINANT B PROTEIN; MEMBRANE PROTEIN; PLACEBO; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; V 710;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG SAFETY; FEMALE; FOLLOW UP; GEOMETRIC MEAN FOLD RISE; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHARMACOLOGICAL PARAMETERS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; CATION TRANSPORT PROTEINS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLACEBOS; RENAL DIALYSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; YOUNG ADULT;

EID: 84865966606     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00034-12     Document Type: Article

References (21)

1. Aronoff GR, Maxwell DR, Batteiger BE, Fineberg NS. 1985. Hepatitis B virus vaccine: a randomized trial of a reduced dose regimen in hemodialysis patients. Am. J. Kidney Dis. 6:170-172. (Pubitemid 15241544)
2. Centers for Disease Control. 2007. Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients-United States, 2005. MMWR Morb. Mortal. Wkly. Rep. 56:197-199.
3. Daum RS, Spellberg B. 2012. Progress toward a Staphylococcus aureus vaccine. Clin. Infect. Dis. 54:560-567.
4. Engemann JJ, et al. 2005. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect. Control Hosp. Epidemiol. 26:534-539. (Pubitemid 40896143)
5. Fowler VG, et al. 2012. Efficacy and safety of V710, a Staphylococcus aureus vaccine, in preventing bacteraemia and/or deep sternal wound infections in patients undergoing cardiac surgery, abstr O164. Abstr. 22nd Eur. Congr. Infect. Dis. Clin. Microbiol., London, United Kingdom; 31 March to 3 April 2012. http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2012.03801.x/pdf.
6. Girndt M, Pietsch M, Kohler H. 1995. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am. J. Kidney Dis. 26:454-460.
7. Harro C, Betts R, Orenstein W. 2010. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. Clin. Vaccine Immunol. 17:1868-1874.
8. Harro C, et al. 2012. The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two phase I studies. Vaccine 30:1729-1736.
9. Kelly-Quintos C, Cavacini LA, Posner MR, Goldmann D, Pier GB. 2006. Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine. Infect. Immun. 74:2742-2750. (Pubitemid 43672983)
10. Kreft B, Klouche M, Kreft R, Kirchner H, Sack K. 1997. Low efficiency of active immunization against diphtheria in chronic hemodialysis patients. Kidney Int. 52:212-216. (Pubitemid 27321833)
11. Kuklin NA, et al. 2006. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun. 74:2215-2223.
12. Li Y, et al. 2009. Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients. Clin. J. Am. Soc. Nephrol. 4:428-434.
13. Litjens NH, Huisman M, van den Dorpel M, Betjes MG. 2008. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J. Am. Soc. Nephrol. 19:1483-1490.
14. Mazmanian SK, Ton-That H, Su K, Schneewind O. 2002. An iron-regulated sortase anchors a class of surface protein during Staphylococcus aureus pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 99:2293-2298. (Pubitemid 34169054)
15. Nissenson AR, et al. 2005. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis. Am. J. Kidney Dis. 46:301-308. (Pubitemid 41040359)
16. Pancari G, et al. 2012. Characterization of the mechanism of protection mediated by CS-D7, a monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB). Front. Cell. Infect. Microbiol. 2:36. doi:10.3389/fcimb.2012.00036.
17. Proctor RA. 2012. Is there a future for a Staphylococcus aureus vaccine? Vaccine 30:2921-2927.
18. Rautenberg P, Teifke I, Schlegelberger T, Ullmann U. 1988. Influenza subtype-specific IgA, IgM and IgG responses in patients on hemodialysis after influenza vaccination. Infection 16:323-328. (Pubitemid 19004302)
19. Reed SD, et al. 2005. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect. Control Hosp. Epidemiol. 26: 175-183. (Pubitemid 40445023)
20. Shinefield HS, et al. 2002. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346:491-496.
21. United States Renal Data System. 2006. United States Renal Data System 2006 annual data report: atlas of end-stage renal disease in the United States. U.S. Department of Health and Human Services, National Institutes of Health, Bethesda, MD.